Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 03, 2023 07:00 ET | Source: Renalytix plc

Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors

LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled...
June 29, 2023 18:01 ET | Source: Renalytix plc

FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease

Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients in the United States Diabetic Kidney Disease is the Leading Cause of End Stage Kidney Disease in the United...
June 15, 2023 07:00 ET | Source: Renalytix plc

KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences

LONDON and SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that three scientific abstracts have been accepted at the upcoming American...
June 09, 2023 07:00 ET | Source: Renalytix plc

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023

LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical...
June 05, 2023 07:00 ET | Source: Renalytix plc

Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9

LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before...
May 25, 2023 07:00 ET | Source: Renalytix plc

Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes

LONDON and CHICAGO, May 25, 2023 (GLOBE NEWSWIRE) -- Renalytix (NASDAQ: RNLX) (LSE: RENX), the first company to develop and commercialize an artificial intelligence (AI) powered in-vitro diagnostic...
April 19, 2023 07:00 ET | Source: Renalytix plc

New Published Real-World Evidence Shows KidneyIntelX™ Utility

Real-World Utility Data Demonstrates KidneyIntelX Optimizes Clinical Management in Early-Stage Chronic Kidney Disease Across Multiple Physician Specialties KidneyIntelX individualizes clinical...
April 12, 2023 07:00 ET | Source: Renalytix plc

Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting

In a clinical decision effectiveness study, KidneyIntelX classified more Black vs non-Black patients as high risk for progression of chronic kidney disease, resulting in increased prescription of...
March 30, 2023 07:00 ET | Source: Renalytix plc

Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results

LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing...
March 22, 2023 07:00 ET | Source: Renalytix plc

Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30

LONDON and SALT LAKE CITY, March 22, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that it will report its second quarter and first half fiscal year 2023...